New-Onset Diabetes in Peritoneal Dialysis Patients – Which Predictors Really Matter?

Jain A.K. , Blake P. , Cordy P. , Garg A.X. Global trends in rates of peritoneal dialysis. J Am Soc Nephrol 2012; 23(3): 533–44.

Rivara M.B. , Mehrotra R. The changing landscape of home dialysis in the United States. Curr Opin Nephrol Hypertens 2014; 23(6): 586–91.

McDonald S.P. , Marshall M.R. , Johnson D.W. , Polkinghorne K.R. Relationship between dialysis modality and mortality. J Am Soc Nephrol 2009; 20(1): 155–63.

Mehrotra R. , Chiu Y. , Kalantar-Zadeh K. , Bargman J. , Vonesh E. Similar outcomes with hemodialysis and peritoneal dialysis in patients with end-stage renal disease. Arch Intern Med 2011; 171(2): 110–8.

Weinhandl E.D. , Foley R.N. , Gilbertson D.T. , Arneson T.J. , Snyder J.J. , Collins A.J. Propensity-matched mortality comparison of incident hemodialysis and peritoneal dialysis patients. J Am Soc Nephrol 2010; 21(3): 499–506.

Selby N.M. , McIntyre C.W. Peritoneal dialysis is not associated with myocardial stunning. Perit Dial Int 2011; 31(1): 27–33.

Misra M. , Vonesh E. , Van Stone J.C. , Moore H.L. , Prowant B. , Nolph K.D. Effect of cause and time of dropout on the residual GFR: a comparative analysis of the decline of GFR on dialysis. Kidney Int 2001; 59(2): 754–63.

Li P.K.T. , Culleton B.F. , Ariza A. , Do J-Y , Johnson D.W. , Sanabria M. Randomized, controlled trial of glucose-sparing peritoneal dialysis in diabetic patients. J Am Soc Nephrol 2013; 24(11): 1889–900.

Li P.K.T. , Dorval M. , Johnson D.W. , Rutherford P. , Shutov E. , Story K. The benefit of a glucose-sparing PD therapy on glycemic control measured by serum fructosamine in diabetic patients in a randomized, controlled trial (IMPENDIA). Nephron 2015; 129(4): 233–40.

Duong U. , Mehrotra R. , Molnar M.Z. , Noori N. , Kovesdy C.P. , Nissenson A.R. Glycemic control and survival in peritoneal dialysis patients with diabetes mellitus. Clin J Am Soc Nephrol 2011; 6(5): 1041–8.

Festa A. , D'Agostino R. , Howard G. , Mykkänen L. , Tracy R.P. , Haffner S.M. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000; 102(1): 42–7.

Pecoits-Filho R. , Carvalho M.J. , Stenvinkel P. , Lindholm B. , Heimbürger O. Systemic and intraperitoneal interleukin-6 system during the first year of peritoneal dialysis. Perit Dial Int 2006; 26(1): 53–63.

Chou C-Y , Liang C-C , Kuo H-L , Chang C-T , Liu J-H , Lin H-H Comparing risk of new-onset diabetes mellitus in chronic kidney disease patients receiving peritoneal dialysis and hemodialysis using propensity score matching. Plos One 2014; 9(2): e87891.

Tien K-J , Lin Z-Z , Chio C-C , Wang J-J , Chu C-C , Sun Y-M Epidemiology and mortality of new-onset diabetes after dialysis: Taiwan national cohort study. Diabetes Care 2013; 36(10): 3027–32.

Dong J. , Yang Z-K , Chen Y. Older age, higher body mass index and inflammation increase the risk for new-onset diabetes and impaired glucose tolerance in patients on peritoneal dialysis. Perit Dial Int 2016; 36(3): 277–83.

American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2012; 35(Suppl 1): S64–71.

Coelho S. , Rodrigues A. Hemoglobin A1c in patients on peritoneal dialysis: how should we interpret it? Ther Apher Dial 2014; 18(5): 375–82.

Davies S.J. , Russell L. , Bryan J. , Phillips L. , Russell G.I. Impact of peritoneal absorption of glucose on appetite, protein catabolism and survival in CAPD patients. Clin Nephrol 1996; 45(3): 194–8.

Wu H-Y , Hung K-Y , Huang J-W , Chen Y-M , Tsai T-J , Wu K-D . Initial glucose load predicts technique survival in patients on chronic peritoneal dialysis. Am J Nephrol 2008; 28(5): 765–71.

Wu H-Y , Hung K-Y , Huang T-M , Hu F-C , Peng Y-S , Huang J-W Safety issues of long-term glucose load in patients on peritoneal dialysis—a 7-year cohort study. Plos One 2012; 7(1): e30337.

Larsen C.M. , Faulenbach M. , Vaag A. , Vølund A. , Ehses J.A. , Seifert B. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 2007; 356(15): 1517–26.

Hemodialysis Novel Therapies (HDNT) Consortium [Internet]. [Accessed 14 October 2015]. Available from: www.hdnt.org.

Bonomini M. , Di Liberato L. , Del Rosso G. , Stingone A. , Marinangeli G. , Consoli A. Effect of an L-carnitine-containing peritoneal dialysate on insulin sensitivity in patients treated with CAPD: a 4-month, prospective, multicenter randomized trial. Am J Kidney Dis 2013; 62(5): 929–38.

Li Y. , Xie Q. , You H. , Tian J. , Hao C. , Lin S. Twelve weeks of pioglitazone therapy significantly attenuates dysmetabolism and reduces inflammation in continuous ambulatory peritoneal dialysis patients—a randomized crossover trial. Perit Dial Int 2012; 32(5): 507–15.

Cioni A. , Sordini C. , Cavallini I. , Bigazzi R. , Campese V.M. Angiotensin receptor blocker telmisartan improves insulin sensitivity in peritoneal dialysis patients. Perit Dial Int 2010; 30(1): 66–71.